Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 15/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.38 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.38 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.38 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18664465 | 0.88 | SSTR4 (0.52) | SSTR4CTSCSSTR1SSTR2SSTR3 | |
| SCHEMBL8860932 | 0.88 | SSTR4 (0.52) | SSTR4CTSCSSTR1SSTR2SSTR3 | |
| SCHEMBL18664463 | 0.88 | SSTR4 (0.52) | SSTR4CTSCSSTR1SSTR2SSTR3 | |
| SCHEMBL25021727 | 0.88 | GNAI3 (0.54) | SSTR4GNAI3GNAO1GNAI1 | |
| SCHEMBL25023253 | 0.88 | GNAI3 (0.54) | SSTR4GNAI3GNAO1GNAI1 | |
| SCHEMBL26724416 | 0.84 | SSTR4 (0.47) | SSTR4CTSCSSTR1SSTR2SSTR3 | |
| SCHEMBL6039537 | 0.81 | SSTR4 (0.49) | SSTR4CTSCSSTR1SSTR2SSTR3 | |
| SCHEMBL5634966 | 0.80 | SSTR4 (0.48) | SSTR4CTSCSSTR1SSTR2SSTR3 | |
| SCHEMBL13652995 | 0.80 | SSTR4 (0.41) | SSTR4CTSC | |
| SCHEMBL4967939 | 0.79 | SSTR4 (0.48) | SSTR4CTSCSSTR1SSTR2SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113929642-B | Dehydroabietylamine silver ion fluorescent probe and preparation method thereof | 南京林业大学 | 2023-04-11 | — | — | CN | disclosed |
| CN-113929642-A | Dehydroabietylamine silver ion fluorescent probe and preparation method thereof | 南京林业大学 | 2022-01-14 | — | — | CN | disclosed |
| US-8106057-B2 | Dihydroxyphenyl isoindolylmethanones | ASTEX THERAPEUTICS, LTD. (GB) | 2012-01-31 | — | — | US | disclosed |
| US-20100286167-A1 | DIHYDROXYPHENYL ISOINDOLYLMETHANONES | ASTEX THERAPEUTICS LTD. (GB) | 2010-11-11 | — | — | US | disclosed |
| US-7754725-B2 | Dihydroxyphenyl isoindolymethanones | ASTEX THERAPEUTICS LTD. (GB) | 2010-07-13 | — | — | US | disclosed |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | ASTEX THERAPEUTICS, LTD. (GB) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286167-A1 | DIHYDROXYPHENYL ISOINDOLYLMETHANONES | HSP90AA1, HSP90AB1, HSP90AB2P | SSTR4 4548/4885CHRNB2 2796/4885CHRNB4 2855/4885 |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | HSP90AB2P, HSP90AA1, HSP90AB1 | SSTR4 4357/4885CHRNB2 3719/4885CHRNB4 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.